Business Wire

Wrth: The Royal Institute of Traditional Arts Captivates Greece with the Intricate 'Al-Qatt Al-Asiri’ Art

Share

Saudi traditional arts are set to reach new global audiences as the Royal Institute of Traditional Arts (Wrth) participates in the Saudi Cultural Week in Greece from September 27 to October 1. The event, titled “The Heritage of Two Cultures," explores Saudi heritage through the lens of "Al-Qatt Al-Asiri" art. Wrth offers a series of interactive workshops, including a highlight on the creation of natural dyes and gypsum carving arts with workshops and hands-on community artworks.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241003645976/en/

Wrth: The Royal Institute of Traditional Arts Captivates Greece with the Intricate 'Al-Qatt Al-Asiri’ Art (Photo: AETOSWire)

As part of Culture Week, five talented Saudi artists lead interactive workshops showcasing the art of gypsum carving with traditional ‘Asiri’ patterns. This unique art form gained international recognition after being inscribed on UNESCO's Intangible Cultural Heritage List in 2017.

Alongside these workshops, visitors can explore the world of natural dyes and witness the skill of Saudi artisans firsthand. A dedicated Wrth pavilion invites participants to join in creating a community artwork by coloring traditional ‘Asiri’ patterns with natural-pigmented dyes. The institution international participation never fails to capture global attention, with visitors eager to engage in hands-on artistic experiences rooted in a rich cultural heritage like that of Saudi Arabia.

Moreover, the presence of Saudi artists often fuels curiosity and sparks conversations, as art enthusiasts from around the world seek to understand the cultural and natural inspirations behind this vibrant and diverse artistic tradition.

International art collaborations play a pivotal role in fostering connections between artists and highlighting the universal appeal of traditional art forms. By blending geometric and botanical motifs from both Greece and Saudi Arabia, these exchanges promote cultural exchange and enhance the global visibility of Saudi art. Furthermore, these initiatives empower Saudi artists with a platform to reach new audiences and strengthen the international presence of Saudi art.

About WRTH:

Wrth: The Royal Institute of Traditional Arts is the leading institution dedicated to preserving and promoting our creative national identity. Through education and preservation, we inspire future generations to acquire and refine these skills, ensuring our creative legacy remains vibrant and celebrated. We invite practitioners, students, and global audiences to engage deeply with these crafts, fostering a dynamic creative future for all.

*Source: AETOSWire

View source version on businesswire.com: https://www.businesswire.com/news/home/20241003645976/en/

Contacts

Mansour Aljabarty
mansourj@ynz.sa

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 13:30:00 EET | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations for treatment-resistant depression (TRD) from 10:00-11:30 am ET on January 7th. “PTSD is one of the most challenging mental health conditions, with approximately 13 million adults in the U.S. living with persistent symptoms and limited treatment options,” said Dr. Guy Goodwin, Chief Medical Officer at Compass Pathways. “We are pleased to advance our clinical development - the unmet need is profound, and it demands bold innovation. We believe COMP360 has the potential to tra

Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 12:07:00 EET | Press release

Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,

ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 11:00:00 EET | Press release

CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including

I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 10:00:00 EET | Press release

I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that underpin public safety, mobility and economic activity. Ramudden operates in markets where demand is steady and growing and benefits from deep commerci

RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 10:00:00 EET | Press release

RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye